Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Inventor:
Bolin; David Robert
Address:
Montclair, NJ
No. of patents:
16
Patents:












Patent Number Title Of Patent Date Issued
8211914 Inhibitors of diacylglycerol acyltransferase July 3, 2012
Provided herein are amides containing at least a four ring structure, which are inhibitors of diacylglycerol acyltransferase and are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.
8211884 Diacylglycerol acyltransferase inhibitors July 3, 2012
Provided herein are compounds of the formula (I): ##STR00001## as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment
8153644 Diacylglycerol acyltransferase inhibitors April 10, 2012
Provided herein are compounds of the formula (I): ##STR00001## as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment
8124766 Inhibitors of diacylglycerol acyltransferase February 28, 2012
Provided herein are compounds of the formula (I): ##STR00001## as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment
8115011 Diacylglycerol acyltransferase inhibitors February 14, 2012
Provided herein are compounds of the formula (I): ##STR00001## as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment
8058299 Diacylglycerol acyltransferase inhibitors November 15, 2011
Provided herein are compounds of the formula (I): ##STR00001## as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment
8039495 Biphenyl carboxylic acids and bioisosteres as glycogen synthase activators October 18, 2011
Provided herein are compounds of the formula (I): ##STR00001## as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment
7947728 Indole and indazole analogs as glycogen synthase activators May 24, 2011
Provided herein are compounds of the formula (I): ##STR00001## as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment
7939569 Aniline analogs as glycogen synthase activators May 10, 2011
Provided herein are compounds of the formula (I): ##STR00001## as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment
7714126 Diacylglycerol acyltransferase inhibitors May 11, 2010
Provided herein are compounds of the formula (I): ##STR00001## as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment
7317125 Diacylglycerol acyltransferase inhibitors January 8, 2008
Provided herein are compounds of the formula (I): ##STR00001## as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment
7067529 Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors June 27, 2006
Compounds of formula I are provided ##STR00001## as well as pharmaceutically acceptable salts and esters thereof, wherein the substituents are as disclosed in the specification. The compounds have utility for the treatment of type 2 diabetes mellitus.
7037924 Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors May 2, 2006
Compounds of formula (I) are provided, ##STR00001## wherein R.sup.1 and R.sup.2 are as designated in the specification. The compounds have utility for the treatment of type 2 diabetes mellitus.
6316593 Synthesis of VIP analog November 13, 2001
This invention relates to a novel process for the synthesis of vasoactive intestinal peptide analog Ac(1-31)-NH2 from four protected peptide fragments.
6080837 Synthesis of VIP analog June 27, 2000
This invention relates to a novel process for the synthesis of vasoactive intestinal peptide analog Ac(1-31)--NH.sub.2 from four protected peptide fragments.
5677419 Cyclic vasoactive peptide analogs October 14, 1997
Analogs of porcine Vasoactive Intestinal Peptide are disclosed. The analogs have been cyclized by the covalent attachment, via an amide bond, of the side-chain carboxy terminus of one amino acid in the peptide chain to the side-chain amino terminus of another amino acid in the peptide ch










 
 
  Recently Added Patents
Vehicle hood
Portion of a display panel with an unhappy facial expression icon
Image correction method
Digital microwave radio link with adaptive data rate
Faucet
Measurement of an analyte on the skin using a hue angle
Data architecture and user interface for plasma processing related software applications
  Randomly Featured Patents
Composition for the topical treatment of rashes, dermatoses and lesions
Method and apparatus for automatically converting phone number while roaming
Apparatus for driving liquid jet head
Pharmacologically active guanidine compounds
Wringer device
Sunlight-energy-storing method
Radiation-resistant polycarbonates
System and method for adaptive maximum likelihood sequence estimation
Scribe mark reader
Lighted display chamber